CNS Demyelinating Autoimmune Diseases - Science topic

Hi Hamidreza,

As Vadim and Georgina said, FTY720 or fingolimod will work in EAE mice model. Sphingosine 1-phosphate receptor (S1PR) is expressed in mouse T cells. Thus, in the same way as the human disorder, EAE animal model will ameloriate with fingolimod. I attach a paper from 12 years ago that describes these effects in the animal model.

I hope you find it useful!

Regards,

Jordi.

The range of symptomatic MS medications is endless, as is its list of symptoms.

As long as MS remains defined by unexplained neurological dysfunctions, no causal treatment is possible. Things are different for the direct venous damages to the brain and the indirect venous damages to the spinal cord shown at www.ms-info.net. But, unfortunately, there is only a minority of physicians willing to deal with these complex issues.

Dear Lina,

I completely agree with Ulf. Ideally, if you have enough cells you could do both with and w/o restimulation in parallel?

I tried to measure ex vivo cytokine production by T cells from the T cell transfer colitis model and while direct ex vivo measurement revealed almost nothing at all, there was considerable cytokine expression (IFNg, IL-17) when I left the cells for 4h with Brefeldin A only to at least allow the cells that have been activated in vivo to accumulate sufficient amounts of cytokine intracellularly in order to be detectable.

Hope that helps.

 Dear Dr. Dieter Huisman,

Thank you for the links to your references. Most of them are unsafe files, Sorry I couldn't read them. But I did have a chance to look at the BCA -Clinic, what a wonderful service. I would like to speak to you and Dr. Nicolaus about our research, as to how we can compliment your institution with the "Multi-Systemic Disease.

Best Regards

Prof. Dr. Shahid Sheikh

Foamy macrophages (gitter cells) do migrate out of the MS plaque into the perivascular space and then into the blood stream.

As stated by Ali there are no currently available approved treatments for SP MS that I am aware of. There is an interesting new immunomodulator which is in clinical trials (http://clinicaltrials.gov/ct2/show/NCT01191996) that may be of value however there is limited data on the companies web site (http://www.innateimmunotherapeutics.com/clinical-trials). I as well as others look forward to seeing data from their clinical trials.